<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04274153</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00227941</org_study_id>
    <nct_id>NCT04274153</nct_id>
  </id_info>
  <brief_title>HPV Vaccination Study in Postpartum Women</brief_title>
  <acronym>PPV</acronym>
  <official_title>A Pilot Study of the Immunogenicity of a Two-dose Protocol for 9-valent Human Papilloma Virus Vaccination in Postpartum Girls and Women (15-45 Years Old) Previously Unvaccinated Against HPV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The human papillomavirus (HPV) is the most common sexually transmitted infection (STI) in the&#xD;
      United States (U.S.) and is responsible for a wide range of conditions, including cancers&#xD;
      within the anogenital tract and the oropharynx. In just the U.S. alone, it's estimated that&#xD;
      HPV causes 330,000 cases of precancerous cervical dysplasia and 12,000 cases of cervical&#xD;
      cancer. The investigators propose a 2-dose HPV vaccination study in women seeking postpartum&#xD;
      care at Johns Hopkins University. The investigators will measure the immunogenicity and&#xD;
      acceptability of the vaccine in the postpartum setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot, non-inferiority clinical trial using historical controls. Participants will&#xD;
      have whole blood drawn at 0 months, 6 months, and 7 months and receive the HPV vaccine at 0&#xD;
      months, 6 months, and 12 months. Each blood draw will consist of one 15mL red top tube to&#xD;
      measure HPV serologies and hormone levels. All blood samples collected will be analyzed at&#xD;
      the end of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity of a two-dose 9-valent HPV vaccination as assessed by antibody titer</measure>
    <time_frame>At the end of the study, up to 2 years</time_frame>
    <description>Measure the immunogenicity of a two-dose 9-valent HPV vaccination regimen in postpartum women previously unvaccinated against the HPV virus. Immunogenicity will be assessed by the antibody responses. Antibody titers will be measured using the Geometric mean titer (GMT) ratio for each HPV type between the 2-dose and the 3-dose historical controls. The Geometric mean titers will be measured using milli Merck units (mMU)/mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody response to the other HPV types</measure>
    <time_frame>At the end of the study, up to 2 years</time_frame>
    <description>The antibody types that will be measured are HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58.&#xD;
The milli Merck units (mMU)/mL of measure will be used to determine antibody response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seropositivity for each HPV type after 1-dose</measure>
    <time_frame>At the end of the study, up to 2 years</time_frame>
    <description>Calculate the percentage of participants that seroconverted and determine if hormone levels are associated with seropositivity and GMTs. This will be measured by milli Merck units (mMU)/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seropositivity for each HPV type after 2-doses</measure>
    <time_frame>At the end of the study, up to 2 years</time_frame>
    <description>Calculate the percentage of participants that seroconverted and determine if hormone levels are associated with seropositivity and GMTs. This will be measured by milli Merck units (mMU)/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with baseline titers suggestive of natural inoculation or prior vaccination</measure>
    <time_frame>At the end of the study, up to 2 years</time_frame>
    <description>Running an assay to measure a participants natural inoculation or prior vaccination before administration of the 1st dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who complete 1-dose, 2-dose, or 3-dose vaccination</measure>
    <time_frame>At the end of the study, up to 2 years</time_frame>
    <description>Calculate the amount of participants that complete 1-dose, 2-dose, or 3- dose vaccination.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>HPV</condition>
  <condition>Immunization</condition>
  <condition>Human Papilloma Virus</condition>
  <arm_group>
    <arm_group_label>Gardasil9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two doses of the 9-valent HPV vaccine to be administered to participants at 0 and 6 months. Additional HPV vaccine dose will be offered after final blood draw at 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gardasil9</intervention_name>
    <description>Two doses of the HPV vaccine across a 12 month period (two doses of 0.5mL).</description>
    <arm_group_label>Gardasil9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants biologically born as females between the ages of 15 through 45 who have&#xD;
             delivered a live born baby within the past 72 hours.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Severe allergic reaction to vaccine components&#xD;
&#xD;
          -  Prior receipt of an HPV vaccine dose&#xD;
&#xD;
          -  Fetal demise or stillbirth&#xD;
&#xD;
          -  Allergy to latex or yeast&#xD;
&#xD;
          -  Moderate or severe acute illness (deemed by the investigator to exclude)&#xD;
&#xD;
          -  Immunosuppression (e.g., HIV, solid organ transplant).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women seeking postpartum care at Johns Hopkins University who self-report never receiving an HPV vaccination.</gender_description>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jenell Coleman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chailee Moss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Betty Chou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jenell Coleman, MD</last_name>
    <phone>410-614-4496</phone>
    <email>colemj@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chailee Moss, MD</last_name>
    <phone>410-550-0337</phone>
    <email>cmoss10@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenell Coleman, MD</last_name>
      <phone>410-614-4496</phone>
      <email>colemanj@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Chailee Moss, MD</last_name>
      <phone>410-550-0337</phone>
      <email>cmoss10@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jenell Coleman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chailee Moss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Betty Chou, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chailee Moss, MD</last_name>
      <phone>410-550-0337</phone>
      <email>cmoss10@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jenell Coleman, MD</last_name>
      <phone>410-614-4496</phone>
      <email>colemanj@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jenell Coleman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chailee Moss, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Betty Chou, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 14, 2020</study_first_submitted>
  <study_first_submitted_qc>February 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human Papilloma Virus</keyword>
  <keyword>HPV</keyword>
  <keyword>Immunization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papilloma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

